Summary Safety Review - Gadolinium based contrast agents - Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects

In 2016, Health Canada reviewed the risk of gadolinium build-up in the brain and potential neurological side effects in light of published studies showing that gadolinium may accumulate in the brain when GBCAs are given repeatedly. The neurological effects of these build-ups are not known.

Data and Resources

Additional Info

Field Value
Last Updated January 16, 2026, 20:46 (UTC)
Created January 16, 2026, 20:46 (UTC)
contains_pii non
crisis_categories Fortes pluies
criticality_level Faible
data_formats HTML
fair_openness Level 2 - Machine-readable
geographic_scope Canada
sensitivity_level Faible
source_inventaire Inventaire_W
source_url https://open.canada.ca/data/en/dataset/7495720d-ee05-4faa-89d4-7211267848a1
subject health_and_safety
update_frequency as_needed
year_most_recent 2024-05-09 14:21:21.249000
year_start 2024-05-07 14:21:53.025000